Fosun Pharma: Registration application of injectable lactose lysozyme approved for review.

Fosun Pharma announced that its holding subsidiary, Suzhou Er Ye Pharmaceutical Co., Ltd., has recently had its registration application for injection lactose erythromycin accepted by the National Medical Products Administration. As of December 2025, the group's cumulative research and development investment in this drug is approximately 6.33 million yuan. According to the latest data from IQVIA CHPA, in 2024, the sales of injection lactose erythromycin in China were approximately 170 million yuan.